Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?  by Meyrier, Alain Y.
Treatment of focal segmental glomerulosclerosis
with immunophilin modulation: when did we stop
thinking about pathogenesis?
Alain Y. Meyrier1
1Department of Nephrology, University Paris-Descartes, Hoˆpital Georges Pompidou and Broussais, Paris, France
Nephrotic focal segmental glomerulosclerosis (FSGS)
represents a difficult therapeutic challenge. FSGS has long
been considered a subset of idiopathic nephrotic syndrome,
lumping together FSGS and minimal change disease (MCD).
The time-honored ‘Shalhoub hypothesis’ has led to treating
FSGS as a T-cell-driven condition in which a lymphokine,
considered without proof as being the ‘glomerular
permeability factor,’ induces proteinuria and podocyte
functional and structural derangement. This has led to trying,
in addition to steroids, every new drug marketed in the field
of organ transplantation, first cyclosporine (CsA) and then
other immunophilin modulators. The fact that alkylating
agents and mycophenolate mofetil have obtained a poor and
inconstant favorable effect, and that rituximab may obtain
remissions, although inconstantly, has not led to
reconsidering the T-cell hypothesis. This wrong thinking has
fostered innumerable, mostly uncontrolled, treatment trials
with various immunosuppressive agents. In fact, clinicians
have not considered the fact that some but not all
immunophilin modulators may be effective as nonspecific
antiproteinuric agents, rather than as immunosuppressive
drugs, and that treatment success does not exclude a non-
immunologic pathophysiology. Recent findings on the mode
of action of CsA and FK-506 have lent support to this
concept. This review should be considered as a plea to
reconsider the pathogenesis of nephrotic FSGS, applying all
efforts to the identification of the factor, or factors,
responsible for nephrotic FSGS, and to fund treatment to
counteract the ‘factor,’ rather than pursuing costly and
non-evidence-based immunosuppressive therapeutic trials.
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Focal segmental glomerulosclerosis (FSGS) is the convenient
term used to define five histopathological subsets of
glomerular changes, categorized by the ‘Columbia classifica-
tion.’1 This clinico-pathological spectrum ranges from the
glomerular tip lesion, a relatively benign entity, to the most
severe cellular lesion, collapsing glomerulopathy. Most are
profusely proteinuric and often stubbornly resist therapy.
This review suggests that the response of nephrotic syndrome
to treatment, especially to treatment with immunophilin
modulators, does not yet provide answers, but rather opens
up a new line of thought with respect to the elusive
pathophysiology of FSGS.
There is no evidence that FSGS and minimal glomerular
changes are the same disease
The debate between defenders and detractors of the unity or
the diversity of FSGS versus minimal glomerular disease
(MCD) is still open,2 despite laboratory evidence pointing to
a different pathogenesis. Shankland et al.3 showed that cyclin-
dependent kinase inhibitor markers, p57 and p27, which
inhibit podocyte proliferation, are expressed in controls and
in MCD but not in FSGS, whereas cyclin-dependent kinase
inhibitors, p21 and KI-67, which elicit podocyte prolifera-
tion, are not expressed in MCD but are expressed in FSGS.3
Garin et al.4 demonstrated that urinary-soluble CD80
excretion increases in nephrotic MCD but not in similarly
proteinuric FSGS.
The concept of a podocytopathy that can be structural in
FSGS and functional in minimal glomerular changes5 may
reconcile nephrologists caring for patients suffering from
‘idiopathic nephrotic syndrome,’ the new denomination for
what was classically known as ‘nephrosis.’ In fact, a concept
can be more or less reassuring to the clinician, who may
wonder how a case of nephrotic syndrome, with no other
lesion than foot-process flattening detected by electron
microscopy and fast remission with steroids, can be the
same disease as the worst form of highly cellular FSGS
leading to end-stage renal insufficiency within months,
despite high-dose steroids and various immunosuppressive
drugs. It has long been established that the response to
corticosteroids is the best prognostic factor of idiopathic
nephrotic syndrome, irrespective of histopathology,5–9 and
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that steroid resistance portends a poor prognosis in nephrotic
FSGS. In fact, the response to corticosteroids has been
nothing but a time-honored means of eschewing the
nosology and the pathophysiology of FSGS and of MCD,
which was more than poorly understood three decades ago.
Moreover, the mode of action of steroids in suppressing
proteinuria is still unclear. It is conceivable that their
genomic and non-genomic effects10 concur to exert a
stabilizing effect on the podocyte cytoskeleton, as well as an
immunosuppressive action on the lymphoid system. In fact,
Peter Mathieson’s group showed that dexamethasone exerts
an effect on podocytes, including on their actin cytoskele-
ton.11 Mathieson, discussing the relationship between
proteinuria and autoimmunity,12 stressed the fact that
podocytes and lymphocytes might share the same pathways
to respond to the action of glucocorticoids.
At any rate, reason tells us that the response of a disease to
treatment is a rather elementary means of extrapolating its
pathophysiology. The same applies to the ‘Shalhoub hypo-
thesis,’ which still seems to be the rationale for treating MCD
and FSGS.
The Shalhoub hypothesis, an apparently right source of
wrong thinking
In 1974, a seminal paper appeared in the Lancet, at a time
when no clear distinction was made between minimal change
disease (MCD) and FSGS.13 Shalhoub listed clinical and
therapeutic reasons for the belief that ‘nephrosis’ is an
immunological condition. Among these reasons stood
clinical observations suggesting that which we now call the
‘idiopathic nephrotic syndrome’ is produced by an abnorm-
ality of the T-cell function, resulting in the secretion of a
chemical mediator that is toxic to GBM. To support his
hypothesis, Shalhoub stressed the lack of evidence of a
humoral antibody response; of remission induced by measles,
which modifies cell-mediated immunity; of the occurrence of
this syndrome in Hodgkin’s disease; and of the therapeutic
benefits of steroids and cyclophosphamide, which abate cell-
mediated responses. Taken together, the data suggested that
idiopathic nephrotic syndrome (lumping MCD and FSGS) is
the clinical expression of a self-limited primary immunolo-
gical derangement. In fact, this reasoning, which applied
rather well to MCD, led without further philosophical
hesitation to the concept that primary FSGS is also a
T-cell-driven condition, in which a cytokine (and Shalhoub
did not necessarily assimilate the ‘chemical mediator’ to a
cytokine) affects GBM permselectivity to serum albumin. In
1974, the notion that FSGS is a structural podocyte disease
was unknown, and the slit diaphragm was a terra incognita.
At any rate, in 1986, the nephrological community embarked
on the Shalhoub hypothesis to treat FSGS with the first
immunophilin modulator available for organ transplanta-
tion, that is, cyclosporine A (CsA).6,14,15 This approach was as
sophisticated as were the first attempts to treat childhood
nephrosis in 1949 with febrile plasma, typhoid vaccine, and
mechlorethamine (Figure 1). The latter, a nitrogen mustard
inherited from World War 1 warfare, won the prize.16 The
rationale for using this alkylating agent was to induce
‘reticuloendothelial suppression.’ Thereafter, an adrenocorti-
cotropic hormone (ACTH) was tried, and successfully so,
before prednisone became available and ACTH obtained
remissions, although mostly partial, of the FSGS-induced
nephrotic syndrome. Interestingly, ACTH can still be used to
suppress proteinuria in various glomerulopathies, not only in
FSGS.17
Cyclosporine A substantially increased the rate of remis-
sion of nephrotic FSGS, which was considered to confirm the
Shalhoub hypothesis, and prompted further trials using
newer immunophilin modulators.8,15 However, in the mean-
time, researchers who analyzed the available data regarding
the cytokine presumably responsible for idiopathic MCD
concluded that the pathogenic cytokine had not been
identified, and that a Th2 predominance was questionable
in MCD.18 Furthermore, all attempts to identify the
‘glomerular permeability factor’ responsible for nephrotic
FSGS led to conflicting results, possibly indicating that there
could conceivably be several chemical substances inducing
Figure 1 | In 1949 the first attempts to treat glomerular disease,
including ‘nephrosis’ were based on febrile plasma, typhoid
vaccine, and mustard gas.16 This bold endeavor calls for a
comment that might apply to the present review: ‘‘One need not
hope in order to undertake, nor succeed in order to persevere,’’ a
wise encouragement to every researcher formulated by William
the Silent, Prince of Orange (1533–1584) whose portrait by
Adriaen Thomasz Key (1544–1589) is represented here. Photo
source: Erich Lessing/Art Resource, NY Mauritshius, The Hague,
The Netherlands.
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this proteinuric podocytopathy. The Savin group had
shown that cyclosporine exerts a favorable effect in vitro on
the glomerular-increased permeability to albumin that
results from the ‘FSGS factor.’19,20 Recent preliminary data
from the same researchers, suggesting that the ‘FSGS factor’
can be counteracted by galactose,21 shed an ironic light on 60
years of various trials using ACTH, steroids, alkylating agents,
and every new drug marketed in the field of organ
transplantation.
Primary steroid-resistant FSGS is not a T-cell-driven
autoimmune disease
Many arguments cast doubt on an autoimmune etiology of
idiopathic nephrotic FSGS in the majority of cases. Contrary
to MCD, about 80% of cases of FSGS are steroid resistant,
with some exceptions such as the glomerular tip lesion.6,22 To
the best of our knowledge, no case of remission with measles
and no documented case of causative Hodgkin’s disease has
been reported with respect to FSGS. Alkylating agents that
abate T-cell cytokine secretion are barely efficient in steroid-
resistant forms.7,8 In addition, among three immunophilin
modulators with proven efficacy in organ transplantation,
two calcineurin inhibitors, cyclosporine and tacrolimus, exert
a favorable effect on proteinuria, which is not the case with
sirolimus, whose mode of action on T cells is different. A T-
cell-driven immune response develops in three phases:8,23 (1)
transcriptional activation of early genes such as the inter-
leukin-2 receptor that elicits progression of T cells from the
G0 to the G1 state. (2) T cells transduce the signal triggered
by specific cytokines that permit entry into the cell cycle,
resulting in (3) clonal expansion and effector functions.
Cyclosporine and tacrolimus share similar pathways to
inhibit the nuclear factor of activated T cells signaling.23
Both bind to the cytosolic FK-binding proteins (FKBP) and
inhibit the first phase. Their effects are beneficial in organ
transplantation and in inflammatory diseases, conditions that
are evidently of an immunological nature. Conversely,
sirolimus, an efficient immunosuppressive drug in organ
transplantation, does not act through the inhibition of
cytokine secretion but on the response to cytokines. The
drug is mostly inefficient, and possibly harmful in the
treatment of FSGS.24 Nevertheless, the quest for the
circulating factor that after renal transplantation induces
first proteinuria, followed weeks later by podocyte lesions
leading to FSGS, seemed to be guided by the obstinate
conviction that the ‘factor’ was a T-cell-driven lymphokine,
and trying drugs that interfere with cytokine production was
in keeping with the ‘Shalhoub hypothesis.’ Over the years,
this conviction has been unmoved by the differing response
of nephrotic proteinuria to immunophilin modulators,
successfully used in organ transplantation and in some
autoimmune diseases.
The last straw that might contribute to toppling the T-cell
Shalhoub hypothesis comes from the observations of a
remission of the nephrotic syndrome obtained with ritux-
imab, a monoclonal antibody that depletes B-cell popula-
tion.25,26 In the same way, mycophenolate mofetil may
inconstantly exert a favorable effect in nephrotic FSGS,
although reliable data with regard to its efficacy await the
results of an ongoing NIH trial.27 In any event, it is worth
noting that mycophenolate mofetil inhibits the formation of
inosine monophosphate, thereby blocking the proliferation
of not only T cells but also B cells.
At this point, we confront the conundrum of a
clinicopathological condition, FSGS, presumed to be caused
by a glomerular permeability factor, the nature of which has
never been elucidated, which poorly responds to corticoster-
oid therapy, still more disappointingly to alkylating agents,
not equally to all immunophilin modulators, and incon-
stantly to mycophenolate mofetil.
Calcineurin inhibitors diminish or suppress proteinuria in
glomerulopathies either with or without an immunological
background
Following the first publications on the favorable effect of
cyclosporine in idiopathic nephrotic syndrome, the drug was
tried in a host of nephrotic glomerular diseases. It appeared
that in a number of glomerulopathies with no immunolo-
gical background, CsA significantly diminished proteinuria.14
This was the case, for instance, in the Alport syndrome and in
diabetic glomerulopathy. The first explanation that came to
mind was that CsA induced afferent arteriole vasoconstric-
tion, which in turn reduced the glomerular filtration rate and
hence the amount of serum albumin entering the proximal
tubule. This hypothesis was not confirmed by animal
experiments. Schrijver et al.28 used a passive model of anti-
GBM nephritis in the mouse to induce proteinuria.
Cyclosporine obtained a considerable reduction of protei-
nuria and of the glomerular filtration rate, but had no effect
on the severity of glomerular lesions. Following treatment
with phenoxybenzamine—a vasodilator—the glomerular
filtration rate was restored to baseline, but the degree of
reduction in proteinuria was unchanged.
Still more intriguing were findings regarding human
disease. Zietse et al.29 studied the effect of cyclosporine in five
cases of MCD and in six cases of idiopathic membranous
glomerulopathy. In MCD, proteinuria decreased from a mean
of 9.5 G to 1.3 G/24 h and in idiopathic membranous
glomerulopathy from 9.9 to 1.8 G/24 h. Dextran clearance
decreased for larger molecules (50–58 A˚). The authors
interpreted the dextran clearance study as showing an
increased charge selectivity in MCD and an increase in pore
size selectivity in idiopathic membranous glomerulopathy.
Ambalavanan et al.30 treated 41 patients with idiopathic
membranous glomerulopathy for 3–6 months with CsA.
Proteinuria decreased from a mean of 7.3 to 3.2 g/24 h. The
glomerular filtration rate remained constant. CsA restored
dextran sieving curves toward normal, lowering the com-
puted fraction of shunt-like pores by 25%, indicating an
enhanced barrier size selectivity. However, repeat biopsies
studied by electron microscopy showed a progression of
glomerular lesions.
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A similar dissociation between the CsA-induced pharma-
cological reduction of proteinuria and the progression of
glomerular lesions was observed by Chen et al.31 in a canine
model of the Alport syndrome. The most unexpected finding
was that, despite developing fraying and splitting of the
GBMs on repeat histology, CsA slowed the pace of
glomerular filtration rate decline in treated dogs. The same
‘renoprotective effect’ was observed by Cattran et al.32 in
human FSGS.
Several hypotheses could be made. The cyclosporine
molecule is highly lipophilic. Does it bind to the slit
diaphragm nephrin–CD2AP–podocin lipid raft complex?33
Does it occupy sites located at the glycocalyx-GBM-slit
diaphragm level to hinder the transit of anionic serum
albumin molecules to Bowman’s space?34 Two recent findings
have shed new light on the quandary. Faul et al.35 published
an elegant study that showed that the antiproteinuric effect of
CsA does not result from the inhibition of the nuclear factor
of activated T cells signaling, but from blocking the
calcineurin-mediated dephosphorylation of the actin-orga-
nizing protein, synaptopodin. This confers a stabilization of
the actin cytoskeleton in podocytes. The antiproteinuric
effect of CsA might explain partial, but clinically beneficial,
remissions in FSGS.32,36 It is conceivable that tacrolimus
diminishes proteinuria through a similar mechanism, but so
far, no study has been undertaken to prove it. However,
preliminary experiments reveal that tacrolimus exerts a
pharmacological action on the transient receptor potential
cation channel 6 (TRPC6), a podocyte membrane molecule,
to diminish proteinuria. TRPC6 mutations may lead to a
hereditary autosomal dominant form of FSGS.37 Taken
together, these observations should foster further research
on the pharmacological action of tacrolimus in reducing the
proteinuria that accompanies various histopathological
subtypes of FSGS.
Why did we stop thinking that treatment success does not
exclude a mechanism other than immunological?
The above data point to a mental block. The pathophysiology
of nephrotic FSGS has never been elucidated. The fact that
the humoral substance that elicits an instant or delayed
relapse of proteinuria in about 30% (but not in all) of
transplanted kidneys38 can be transmitted from mother to
fetus39 and may be removed by plasmapheresis;40 that its
unknown source or effect is, albeit inconstantly, counteracted
by steroids and immunosuppressors including mycophenolic
acid41 is proven. That the ‘factor’ is the same substance in all
forms of FSGS, irrespective of histology, response to
treatment and early relapse, delayed relapse, or no relapse
on a transplanted kidney, is a postulate that does not rest on
consistent evidence. The belief that the ‘factor’ is a T-cell-
driven cytokine may be interpreted as the pursuit of a mirage.
In fact, the response to treatment might be an incentive to
start thinking. The poor results of alkylating agents on FSGS-
induced nephrotic syndrome cast doubt on the T-cell
Shalhoub hypothesis. Moreover, the failure of sirolimus to
obtain the same remission rate as that of CsA and tacrolimus
may indicate that FSGS does not necessarily result from a
specific immunological derangement. Above all, the anti-
proteinuric effect of cyclosporine and tacrolimus involving a
direct effect on some of the slit-diaphragm molecules puts a
black mark on the autoimmune nature of FSGS. In fact CsA,
and possibly tacrolimus, might be considered as antiprotei-
nuric pharmacological agents, such as angiotensin antago-
nists,41 and also ACTH,17 rather than as immunosuppressive
drugs in this particular indication.
Can we change tracks for a more sensible approach?
The Shalhoub hypothesis was seminal, in that it fostered
therapeutic endeavors that led to a successful treatment of
MCD. However, it caused the nephrological community to
embark on a dead end with respect to FSGS. This
clinicopathological entity is too complex to accept without
serious reservations with regard to the results of so many
immunosuppressive trials that often neglect, for instance, the
genetic background that plays a major role in black patients
of African ancestry,42,43 or mix up adult and childhood cases,
considering that in children the disease might be less severe
than in adults.44
We should change tracks and consider that the issue at
stake is not yet to determine the source of the ‘factor,’ or
factors that induce podocyte dysregulation, nephrotic
syndrome, and nephron loss, but to decipher its—or
their—nature. In our days of molecular biology and
proteomics, the time has come to grapple with the
identification of the villain, to determine its identity, and
possibly find along the way that there is not a single culprit.
Appropriate means of counteracting its noxious effects on the
glomerulus cannot but follow. This might toll the knell for
the innumerable and costly uncontrolled clinical trials7,9 that
continue to keep nephrologists in a quagmire of uncertainty
regarding the pathophysiology, and hence the treatment of
FSGS.
DISCLOSURE
The author declares he has received travel and speaker’s grants from
Novartis-Pharma.
ACKNOWLEDGMENTS
This review is dedicated to J. Stewart Cameron.
REFERENCES
1. D’Agati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal
segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;
43: 368–382.
2. Meyrier A, Niaudet P. Minimal changes and focal-segmental
glomerulosclerosis. In: AM Davison, JS Cameron, J-P Gru¨nfeld, E Ritz, C
van Ypersele, C Ponticelli, C Winearls (eds). Oxford Textbook of Clinical
Nephrology, vol. 1, 3rd edn. Oxford University Press: Oxford, 2005,
pp 439–469.
3. Shankland SJ, Eitner F, Hudkins KL et al. Differential expression of cyclin-
dependent kinase inhibitors in human glomerular disease: role in
podocyte proliferation and maturation. Kidney Int 2000; 58: 674–683.
4. Garin EH, Diaz LN, Mu W et al. Urinary CD80 excretion increases in
idiopathic minimal-change disease. J Am Soc Nephrol 2009; 20:
260–266.
490 Kidney International (2009) 76, 487–491
min i rev iew A Meyrier: Immunophilin modulators in FSGS
5. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the
podocytopathies: a reassessment of the primary nephrotic diseases. Clin J
Am Soc Nephrol 2007; 2: 529–542.
6. Chun MJ, Korbet SM, Schwartz MM et al. Focal segmental
glomerulosclerosis in nephrotic adults: presentation, prognosis, and
response to therapy of the histologic variants. J Am Soc Nephrol 2004; 8:
2169–2177.
7. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for
focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev
2008; 16:CD003233.
8. Meyrier A. An update on the treatment options for focal segmental
glomerulosclerosis. Expert Opin Pharmacother 2009; 10: 615–628.
9. Meyrier A. Management of idiopathic nephrotic syndrome in adults:
Minimal change disease and focal segmental glomerulosclerosis. In:
Donald A. Molony, Jonathan C. Craig (eds). Evidence-Based Nephrology,
Chapter 13 BMJ Publishing Group: Wiley-Blackwell, 2009, pp 149–157.
10. Buttgereit F, Straub RH, Wehling M et al. Glucocorticoids in the treatment
of rheumatic diseases. An update on the mechanisms of action. Arthr and
Rheum 2004; 50: 3408–3417.
11. Xing CY, Saleem MA, Coward RJ et al. Direct effect of dexamethasone on
human podocytes. Kidney Int 2006; 70: 1038–1045.
12. Mathieson PW. Proteinuria and autoimmunity-An overstated
relationship? New Engl J Med 2008; 359: 2492–2494.
13. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T cell
function. Lancet 1974; ii: 556–559.
14. Meyrier A. Treatment of glomerular disease with cyclosporine A. Nephrol
Dial Transplant 1989; 4: 923–931.
15. Meyrier A. Treatment of idiopathic nephrosis by immunophilin
modulation. Nephrol Dial Transplant 2003; 18(suppl 6): vi79–vi86.
16. Chasis H, Goldring W, Baldwin DS. Effect of febrile plasma, typhoid
vaccine and nitrogen mustard on renal manifestations of human
glomerulonephritis. Proc Soc Exp Biol Med 1949; 71: 565.
17. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic
syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant
2004; 19: 1305–1307.
18. Araya CE, Wasserfall CH, Brusko TM et al. A case of unfulfilled
expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome.
Pediatr Nephrol 2006; 21: 603–610.
19. Sharma R, Savin VJ. Cyclosporine prevents the increase in glomerular
albumin permeability caused by serum from patients with focal
segmental glomerulosclerosis. Transplantation 1996; 61: 381–383.
20. Sharma R, Sharma M, Ge X et al. Cyclosporine protects glomeruli from
FSGS factor via an increase in glomerular cAMP. Transplantation 1996; 62:
1916–1920.
21. Savin VJ, McCarthy ET, Sharma R et al. Galactose binds to focal segmental
glomerulosclerosis permeability factor and inhibits its activity. Transl Res
2008; 151: 288–292.
22. Stokes BM, Markowitz GS, Lin J et al. Glomerular tip lesion: a distinct
entity within the minimal change disease/focal segmental
glomerulosclerosis spectrum. Kidney Int 2004; 65: 1690–1702.
23. Rao A. Signaling to gene expression: calcium, calcineurin and NFAT. Nat
Immunol 2009; 10: 3–5.
24. Fervenza FC, Fitzpatrick PM, Mertz J et al. Acute rapamycine
nephrotoxicity in native kidneys of patients with chronic
glomerulonephritis. Nephrol Dial Transplant 2004; 19: 1288–1292.
25. Pescovitz M, Book BK, Sidner RA. Resolution of recurrent focal segmental
glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med
2006; 354: 1961–1963.
26. Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new
therapeutic hope? Nephrol Dial Transplant 2008; 23: 11–17.
27. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in
lupus nephritis and other glomerular diseases. Nat Clin Pract Nephrol
2009; 5: 132–142.
28. Schrijver G, Assmann KJ, Wetzels JF et al. Cyclosporin A reduces
albuminuria in experimental anti-GBM nephritis independently from
changes in GFR. Nephrol Dial Transplant 1995; 10: 1149–1154.
29. Zietse R, Wenting GJ, Kramer P et al. Effects of cyclosporin on glomerular
barrier function in nephrotic syndrome. Clin Sci (Lond) 1992; 82:
641–650.
30. Ambalavanan S, Fauvel JP, Sibley RK et al. Mechanism of the
antiproteinuric effect of cyclosporine in membranous nephropathy. J Am
Soc Nephrol 1996; 7: 290–298.
31. Chen D, Jefferson B, Harvey SJ et al. Cyclosporine A slows the progressive
renal disease of Alport syndrome (X-linked hereditary nephritis): results
from a canine model. J Am Soc Nephrol 2003; 14: 690–698.
32. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine
in patients with steroid-resoistant focal segmental glomerulosclerosis.
Kidney Int 1999; 56: 2220–2226.
33. Schwarz K, Simons M, Reiser J et al. Podocin, a raft-associated component
of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin
Invest 2001; 108: 1621–1629.
34. Singh A, Satchell SC, Neal CR et al. Glomerular endothelial glycocalyx
constitutes a barrier to protein permeability. J Am Soc Nephrol 2007; 18:
2885–2893.
35. Faul C, Donnelly FC, Merscher-Gomez S et al. The actin cytoskeleton of
kidney podocytes is a direct target of the antiproteinuric effect of
cyclosporin A. Nat Med 2008; 14: 931–938.
36. Troyanov S, Wall CA, Miller JA, et al., Toronto Glomerulonephritis Registry
Group. Focal and segmental glomerulosclerosis: definition and relevance
of a partial remission. J Am Soc Nephrol 2005; 16: 1061–1068.
37. Winn MP. Young Investigator Award: TRP’ing into a new era for
glomerular diseases. J Am Soc Nephr 2008; 19: 1071–1075.
38. Artero M, Biava C, Amend W et al. Recurrent focal glomerulosclerosis:
natural history and response to therapy. Am J Med 1992; 92:
375–383.
39. Kemper MJ, Wolf G, Mu¨ller-Wiefel DE. Transmission of glomerular
permeability factor from a mother to her child. N Engl J Med 2001; 344:
386–387.
40. Feld S, Figueroa P, Savin V et al. Plasmapheresis in the treatment of
steroid-resistant focal segmental glomerulosclerosis. Am J Kidney Dis
1998; 32: 230–237.
41. Wilmer WA, Rovin BH, Hebert CJ et al. Management of glomerular
proteinuria: a commentary. J Am Soc Nephrol 2003; 14: 3217–3232.
42. Crook ED, Habeeb D, Gowdy O et al. Effects of steroids on focal
segmental glomerulosclerosis in a predominantly African-American
population. Am J Med Sci 2005; 330: 19–24.
43. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk
gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:
1175–1184.
44. Silverstein DM, Craver R. Presenting features and short-term outcome
according to pathologic variant in childhood primary focal segmental
glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 700–707.
Kidney International (2009) 76, 487–491 491
A Meyrier: Immunophilin modulators in FSGS min i rev iew
